Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2014-10-13 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 96 pages 4.5MB
Regulatory Filings
2014-10-13 English
Director Appointments 3 pages 303.4KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Admedus Limited dated 10 October 2014. It announces the appointment of two new board directors, Mr. John Seaberg and Mr. Wayne Paterson, detailing their backgrounds and qualifications. There is no financial data, report, or regulatory filing referenced beyond the announcement itself. The content focuses solely on changes to the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length (7062 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2014-10-09 English
Admedus to showcase CardioCel at EACTS Annual Meeting 2 pages 280.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Limited about their participation and showcasing of their product CardioCel at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting. It includes details about the event dates, locations, and presentations but does not contain any financial data, management changes, voting results, or regulatory filings. It is a corporate announcement about an upcoming event and product showcasing rather than a financial report, regulatory filing, or management information. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a miscellaneous announcement that does not fit other specific categories.
2014-10-09 English
Appendix 3B 15 pages 640.9KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX) by Admedus Ltd. It details the exercise of options and the issue of shares, including the number of shares issued, issue price, and purpose of the issue. The document includes regulatory references to the Corporations Act and ASX Listing Rules, and it is a formal announcement of new securities issued and their quotation on the ASX. The content is focused on capital raising and share issuance rather than financial results, management changes, or other report types. The document is lengthy (15,000 characters) and contains detailed information about the share issue, consistent with a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-10-06 English
Admedus announces further data from HSV-2 Trial 5 pages 427.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Ltd reporting clinical trial results for a Phase I Herpes Simplex Virus vaccine study. It details safety outcomes, immune response data, and plans for Phase II trials. The content is focused on clinical trial progress and scientific data rather than financial results or regulatory filings. It is not a full financial report, audit report, or earnings release. It is also not a presentation, management change, or voting result announcement. The document is a corporate announcement about clinical trial data, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2014-10-01 English
Becoming a substantial holder 3 pages 1.4MB
Regulatory Filings
2014-09-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.